Rosoxacin: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 06:40, 22 September 2010 editحسن علي البط (talk \| contribs)Extended confirmed users, Pending changes reviewers19,940 editsm Adding category Category:Quinolone antibiotics (using HotCat)← Previous edit		Revision as of 06:45, 22 September 2010 edit undoحسن علي البط (talk \| contribs)Extended confirmed users, Pending changes reviewers19,940 editsm Adding category Category:Pyridines (using HotCat)Next edit →
Line 45:		Line 45:

	]		]
			]

Revision as of 06:45, 22 September 2010

Pharmaceutical compound

Rosoxacin
Clinical data

ATC code	J01MB01 (WHO)
Identifiers
IUPAC name 1-Ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
CAS Number	40034-42-2
PubChem CID	287180
CompTox Dashboard (EPA)	DTXSID90193091
ECHA InfoCard	100.049.763
Chemical and physical data
Formula	C₁₇H₁₄N₂O₃
Molar mass	294.30 g/mol g·mol
(verify)

Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.

It was developed by Sanofi-Synthelabo (now part of sanofi-aventis).

It is classified as first generation.

References

Przybilla B, Georgii A, Bergner T, Ring J (1990). "Demonstration of quinolone phototoxicity in vitro". Dermatologica. 181 (2): 98–103. doi:10.1159/000247894. PMID 2173670.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Antibacterials that inhibit nucleic acid (J01E, J01M)

Antifolates
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)

DHFR inhibitor

2,4-Diaminopyrimidine

Sulfonamides
(DHPS inhibitor)

Short-acting	Sulfaisodimidine Sulfamethizole Sulfadimidine (Sulfamethazine, Sulfadimerazine, Sulfadimezine) Sulfapyridine (Sulfasalazine) Sulfafurazole (Acetyl sulfisoxazole) Sulfanilamide Prontosil Sulfathiazole (Phthalylsulfathiazole, Succinylsulfathiazole) Sulfathiourea
Intermediate-acting	Sulfamethoxazole Sulfadiazine Sulfamoxole
Long-acting	Sulfadimethoxine Sulfadoxine Sulfalene Sulfametomidine Sulfametoxydiazine Sulfamethoxypyridazine Sulfaperin Sulfamerazine Sulfaphenazole Sulfamazone
Other/ungrouped	Mafenide Sulfacetamide Sulfaclozine Sulfadicramide Sulfaguanidine Sulfametrole Sulfanitran

Combinations

Other DHPS inhibitors

Quinolones
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)

1st generation

Fluoroquinolones

2nd generation	Ciprofloxacin Ofloxacin Enoxacin Fleroxacin Lomefloxacin Nadifloxacin/Levonadifloxacin/Alalevonadifloxacin Norfloxacin Pefloxacin Rufloxacin
3rd generation	Levofloxacin Balofloxacin Grepafloxacin Pazufloxacin Sparfloxacin Temafloxacin Tosufloxacin
4th generation	Besifloxacin Delafloxacin Gatifloxacin Finafloxacin Gemifloxacin Moxifloxacin Clinafloxacin Garenoxacin Prulifloxacin Sitafloxacin Trovafloxacin/Alatrofloxacin
Veterinary	Danofloxacin Difloxacin Enrofloxacin Ibafloxacin Marbofloxacin Orbifloxacin Pradofloxacin Sarafloxacin

Newer non-fluorinated

Related (DG)

Aminocoumarins: Novobiocin

Anaerobic DNA
inhibitors

Nitroimidazole derivatives	Secnidazole

RNA synthesis

Rifamycins/ RNA polymerase	Rifampicin Rifabutin Rifapentine Rifaximin Rifalazil
Lipiarmycins	Fidaxomicin

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:

Revision as of 06:45, 22 September 2010

See also

References